PD-L1 antibody (AA 18-227)

Catalog No. ABIN5027432

This anti-PD-L1 antibody is a Rabbit Polyclonal antibody detecting PD-L1 in WB. Suitable for Human.

Quick Overview for PD-L1 antibody (AA 18-227) (ABIN5027432)

Target: PD-L1 (CD274 (PD-L1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PD-L1 antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-PD-L1 Antibody

Binding Specificity: AA 18-227

Purification: Protein A Chromatography

Immunogen: A partial length recombinant PDL1 protein (amino acids 18-227) was used as the immunogen for this antibody.

Isotype: IgG

Application Details

Application Notes: WB: 2-4 μg/mL

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: PBS containing 0.05 % BSA, PH 7.4

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

Target Details for PD-L1

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: PD-L1 / CD274

Background: Programmed death ligand 1/PD-L1 (also called B7-H1 and CD274) is a T cell inhibitory molecule that is expressed on antigen presenting cells (APC) leading to T cell anergy and/or apoptosis upon ligation to its receptor Programmed death-1 (PD-1, CD279) on T cells. PD-L1 is expressed on tumor cells of a subset of breast cancer patients. It could also induce EMT and enhance RCC cell cancer stemness through up-regulation of SREBP-1c. Blocking the immunosuppressive PD-1/PD-L1 pathway has antitumor activity in multiple cancer types, and PD-L1 expression on tumor cells and infiltrating myeloid cells correlates with the likelihood of response.

Molecular Weight: 33 kDa

Gene ID: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints